Document Detail


Current treatment of acute myeloid leukemia.
MedLine Citation:
PMID:  23014187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: The objectives of this review are to discuss standard and investigational nontransplant treatment strategies for acute myeloid leukemia (AML), excluding acute promyelocytic leukemia.
RECENT FINDINGS: Most adults with AML die from their disease. The standard treatment paradigm for AML is remission induction chemotherapy with an anthracycline/cytarabine combination, followed by either consolidation chemotherapy or allogeneic stem cell transplantation, depending on the patient's ability to tolerate intensive treatment and the likelihood of cure with chemotherapy alone. Although this approach has changed little in the last three decades, increased understanding of the pathogenesis of AML and improvements in molecular genomic technologies are leading to novel drug targets and the development of personalized, risk-adapted treatment strategies. Recent findings related to prognostically relevant and potentially 'druggable' molecular targets are reviewed.
SUMMARY: At the present time, AML remains a devastating and mostly incurable disease, but the combination of optimized chemotherapeutics and molecularly targeted agents holds significant promise for the future.
Authors:
Gail J Roboz
Related Documents :
23007147 - Mitomycin c in combination with vinorelbine in anthracycline- and/or taxane-pretreated ...
12932387 - Imatinib for systemic mast-cell disease.
12970767 - Serial minimal residual disease (mrd) analysis as a predictor of response duration in p...
23116577 - Synovial cell sarcoma of the larynx.
2599467 - Prognostic value of the rupture of the capsule in stage i epithelial ovarian carcinoma.
7633167 - Characterization and prediction of ivf cycles generating "slow-cleaving" embryos.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in oncology     Volume:  24     ISSN:  1531-703X     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-03-28     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  711-9     Citation Subset:  IM    
Affiliation:
Leukemia Program, Weill Medical College of Cornell University, The New York Presbyterian Hospital, New York, New York 10065, USA. gar2001@med.cornell.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anthracyclines / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azacitidine / administration & dosage,  analogs & derivatives
Consolidation Chemotherapy
Cytarabine / administration & dosage
Humans
Individualized Medicine
Induction Chemotherapy
Leukemia, Myeloid, Acute / drug therapy*,  genetics
Molecular Targeted Therapy
Stem Cell Transplantation
Chemical
Reg. No./Substance:
0/Anthracyclines; 147-94-4/Cytarabine; 320-67-2/Azacitidine; 776B62CQ27/decitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients w...
Next Document:  Venous thromboembolism in the hematologic malignancies.